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1267replacement (TAVR). Furthermore, our study pro-
vides the asked for proof of the turbulence-induced
cleavage of proaggregation proteins (1) for the TAVR
population.
In summary, TAVR as well as surgical aortic valve
replacement lead to a resolution of high-molecular
weight multimer (HMW-MM) deﬁciency/acquired
von Willebrand-syndrome in patients with severe
aortic stenosis. However, PVL as well as prosthesis-
patient mismatch lead to persistent/recurrent factor
deﬁciency in the respective treatment modalities,
with severe (i.e., HMW-MM–deﬁcient) prosthesis-
patient mismatch appearing to occur more fre-
quently with surgical aortic valve replacement (2,3).
As of now and from a pathophysiological standpoint,
these ﬁndings fuel the thesis of PVL ultimately
translating into a HMW-MM-associated bleeding
diathesis and therefore increased mortality (4). But
this applies possibly even more so to patients with
atrial ﬁbrillation/atrial ﬂutter in need of oral anti-
coagulation or triple therapy after TAVR. Whether
HMW-MM/PVL status after TAVR should be incorpo-
rated into the post-procedural anticoagulant strategy
in order to reduce bleeding in this subset of patients,
reﬂecting up to 40% of the TAVR population, needs to
be clariﬁed by future studies.
Furthermore, with HMW-MM deﬁciency as an un-
derlying mechanism of PVL-associated mortality, ef-
forts to sidestep PVL-induced HMW-MM deﬁciency
are the logical primary consequence. Congruously,
HMW-MM reﬂected by platelet function analyzer-
closure time adenine DI-phosphate have just lately
been suggested to be capable of guiding these efforts
intraprocedural (5).
Deﬁnite evidence for the joint thesis thoughwill onlybe
available if future randomized trials reducing major late
bleeding complications demonstrate improved survival (1)
in a number of patients allowing deﬁnite conclusions.
With this in mind, consolidating the work of Généreux
et al. (4) providing bleeding-associated mortality as
driving force and target, ourwork indicating HMW-MM as
themissing link of bleeding associatedmortality and PVL,
and the work of Van Belle et al. (5) providing a technical
suggestion for intraprocedural HMW-MM-guided PVL
avoidance, ﬁnal clariﬁcation seems to be within reach.*Tobias Spangenberg, MD
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of Residual Atrial Septal
Defect Following
Transseptal Catheterization
for Intracardiac Interventional
ProceduresIatrogenic residual atrial septal defect (rASD)
following transseptal catheterization (TC) is a risk of
many interventional procedures. In a recent issue of
JACC: Cardiovascular Interventions, Schueler et al. (1)
reported a 50% rASD persistence rate after trans-
catheter mitral valve repair using the MitraClip sys-
tem (Abbott Vascular, Abbott Park, Illinois). The
assessment was made at 6-month transesophageal
echocardiography (TEE) follow-up. They concluded
that the persistent interatrial shunting was associated
with worse clinical outcomes and increased mortality.
However, there are some important deﬁciencies in
their methodology and data presentation that require
clariﬁcation.
The size of rASD and the time course for possible
regression are critical parameters that will affect clin-
ical hemodynamic and cardiac function. Previous
studies using Mullins TC sheath (Medtronic,
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1268Minneapolis, Minnesota) with an 8-F (2.64 mm)
diameter for atrial ﬁbrillation ablation (2) and
Watchman TC sheath (Boston Scientiﬁc, Natick, Mas-
sachusetts) with a 12-F (3.96 mm)/14-F (4.62 mm)
diameter for left atrial appendage closure (3) indicate
that TC can cause acute rASD with left-to-right shunt
immediately after TC. The rASD after TC appears to
continuously reduce in size (<3 to 4 mm) acutely
within 6 min (2) and during follow-up 3 to 45 days, and
typically resolves completely (8-F Mullins sheath) (2)
or in >90% of patients (12/14-F Watchman sheath) (3)
by 12 to 13 months. The size measured <3 to 4 mmwith
left-to-right shunt appeared to be clinically insigniﬁ-
cant (2,3).
Schueler et al. (1), using a much larger 21-F
(6.93 mm) TC sheath in 66 patients with symp-
tomatic mitral regurgitation (MR)/heart failure
undergoing the MitraClip procedure, reported a per-
sistent rASD with maximal diameters of 4.3  1.7 mmFIGURE 1 ICE of rASD With a Right-to-Left-Flow Shunting and Tricus
Interventional Procedure
Intracardiac echocardiographic (ICE) imaging with the transducer placed
isolation for paroxysmal atrial ﬁbrillation. Transseptal catheter sheath (8
residual atrial septal defect (size measured 3.5 mm and 3.7 mm, respect
immediately following transseptal catheterization and LA ablation proced
regurgitant ﬂow velocity 2.6 m/s with estimated pulmonary artery systol
severely torrential tricuspid regurgitant ﬂow (arrows, mosaic red color)
regurgitant ﬂow velocity 2.0 m/s with an underestimated PASP (30 mm
valve.and minimal diameters of 3.8  2.1 mm measured at
6-month follow-up. However, they did not provide
quantitative measurements regarding the incidence
and size of the rASD immediately after the proce-
dure. Acute rASD size regression does occur and
would have been helpful to determine change over
time (2). In addition, several issues in the method-
ology and measured TEE parameters need to be
clariﬁed. Schueler et al. (1) provide an illustration,
Figure 1C, to show a right-to-left shunt of rASD
even though right-to-left shunt was reported in only
2 of 33 patients with persistent rASD at 6-month
follow-up. However, Figure 1C (even taking the mis-
matched legend into account) does not showa right-to-
left shunt. The mosaic (bluish) shunting ﬂow is
directed from the top site (left atrium) downward to
the anterior right atrium as indexed by the fan-shaped
ﬂow direction. A large space (ﬁlled with cutoff red co-
lor) indicates that the imaging frame was frozen orpid Regurgitation Following Transseptal Catheterization and
in the right atrium (RA) in 2 patients with successful pulmonary vein
-F) (arrow) during the left atrial (LA) ablation procedure (A and D);
ively) with right-to-left-ﬂow shunting (arrow, mosaic bluish color)
ure (B and E); ICE with continuous-wave Doppler measured tricuspid
ic pressure (PASP) 41 mm Hg (C); ICE with color ﬂow imaging showed
(F), but ICE with continuous-wave Doppler measured tricuspid
Hg). Ao ¼ aorta; rASD ¼ residual atrial septal defect; tv ¼ tricuspid
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1269stopped with signiﬁcant artifact on a nonfocused and
off-axis frame shown in the display. With routine
clinical application of intracardiac echocardiography
in more than 3,000 cases of left heart ablation,
we noted that a right-to-left-ﬂow shunting of rASD can
be occasionally detected immediately following TC
(Figure 1) when a patient has signiﬁcantly increased
pulmonary artery systolic pressure (PASP) (Figures 1A
to 1C) or right heart dysfunction (Figures 1D to 1F).
Schueler et al. (1) did not provide clear hemodynamic
and cardiac functional evidence for worse clinical
outcome and increased mortality related to persistent
rASDwith further increased PASP, severity of tricuspid
regurgitation, or a right-to-left-ﬂow shunt at their 6-
month follow-up. Of note, Schueler et al. (1) provided
discrepant baseline echocardiographic measurements
between left ventricular diastolic volume (LVVd) and
end-diastolic dimension (LVEDD) for the patients with
rASD (191.6  75.3 ml and 7.3  0.7 cm, respectively)
and no rASD (198.4  80.2 ml and 6.1  0.7 cm,
respectively) in Table 3. The similar discrepancy is also
noted between LV systolic volume and LV end-systolic
dimension (LVESD) for these 2 patient groups. The
LVEDD and LVESD are clinically reliable parameters,
especially for patients with volume overload from
MR, which have been used as rough surrogates for pre-
load and afterload, respectively (4). These measure-
ment discrepancies make it difﬁcult to understand
which parameter is more accurate. However, in Ta-
ble 4, echocardiographic measurements of patients in
follow-up only used the LVVd parameter, without
including LVEDD measurements (1). Finally, in order
to properly interpret the cause of increased mortality
in these patients, the analysis should include all
available data through the last available follow-up
echocardiographic studies. Obviously, severe func-
tional MR and signiﬁcantly dilated LVEDD and LVESD
at baseline are associatedwith increasedmortality, not
necessarily related to rASD with left-to-right shunt.
Iatrogenic rASD and its clinical effects, especially
when using a large TC sheath, need further study. The
investigators should be congratulated for reporting a
high persistence of rASD at 6-month follow-up when
using 21-F TC sheath for the MitraClip procedure.
However, their data missed the opportunity for
quantitative assessment over time on the size and
ﬂow features of rASD. Care is needed to identify he-
modynamically signiﬁcant changes and their impact
on cardiac function and hemodynamics.*Jian-Fang Ren, MD
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1667–74.REPLY: Quantitative Evaluation of Residual
Atrial Septal Defect Following Transseptal
Catheterization for Intracardiac Interventional
ProceduresWe thank Dr. Ren and colleagues for the comment on
our paper (1).
Iatrogenic atrial septal defect (iASD) sizes were
considerably smaller in our study than Ren et al. (2)
found in previous analyses of procedures using
smaller transseptal sheaths. They found that iASDs
<4 mm had no clinical signiﬁcance. In our opinion,
the cited studies are not comparable to our results
due to the fact that we treated mainly typical heart
failure patients with a signiﬁcant proportion of pa-
tients with severely reduced left ventricular ejection
fraction (LVEF). Assuming that in our cohort, left
atrial pressures are signiﬁcantly higher than in a
healthier cohort, the hemodynamic consequences
and persistence rates may differ signiﬁcantly due to
markedly increased shunt volumes. In fact, the he-
modynamic relevance of ASD must not be calculated
based only on the sheer and may have overestimated
shunt sizes. Hemodynamic consequences are directly
related to the associated shunt volumes, and high-
ﬂow shunts with small diameters can lead to signiﬁ-
cant volume overload.
We cannot follow the comment of Dr. Ren and
colleagues We showed clearly a right-to-left shunting.
In our opinion, it is not suitable to compare
